Thistherapeutic effect was confirmed in the murine 4 T1 breast tumor model with long-termsurvival 4 of 5 mice receiving combined mAb/cisplatin or paclitaxel treatment.Interestingly, combination of either anti-PD-1 or anti-GITR mAb and chemotherapeuticdrugs did not eradicate most of tumor, underscoring the necessity of synergistic PD-1blockade and GITR triggering in eliciting an optimal antitumor effects. This evidence concerns the gene TNFRSF18 and breast neoplasm.